2,833 publications from this institution
Some research has been done on connections between uses of oral ways and written means in helping relationships. In particular, becoming so involved in their writings, psychoanalysts publish clinical cases about ex-patients cures. Nevertheless, the effects of the reading of his case by the concerned ex-analysand are a topic on which very few data are available, except for Serge Doubrovsky’s example (1999).In this field, the question which is studied here is : what would be the effects on a former analysand, Jacques, of his readings of his case published in two documents (a book and an article) written by his ex-psychoanalyst. The situation is unusual because their comparison leads to assuming a sort of parapraxis by the author during the writing of that article because of the disappearance of an essential paragraph appearing in the book. This kind of lapse by the analyst would illustrate Dona Rudelic-Fernandez’s hypothesis (1994) according to which the study of a clinical may reveal inanalysed elements of the concerned cure.Thus, an unforeseen and unlikely device would have been set up, via some published writings or intended to be so. And the analysis of an analyst’s article by the former analysand would have contributed, besides other perlaborations, to his autonomisation with regard to his transfer on his former analyst.This hypothetical and provisional conclusion cannot be generalized. Like this, in Plato’s Pharmacy (1997), Jacques Derrida commenting on Plato’s Phaedra, notices that the writing may form either a narcotic or a medicine for the life of the memory.
The first ICUs were established in the late 1950s and the specialty of critical care medicine began to develop. Since those early days, huge improvements have been made in terms of technological advances and understanding of the pathophysiology and pathogenesis of the disease processes that affect critically ill patients. Progress in therapeutics has been less dramatic, but process of care has improved steadily with important changes, including less iatrogenicity, better communication with patients and families, and improved teamwork, which have helped improve outcomes for ICU patients. Critical care medicine is one of the fastest-growing hospital specialties and, looking back, it is clear just how far we have come in such a relatively short period of time. With the ICU set to occupy an increasingly important place in hospitals worldwide, we must learn from the past and wisely embrace new developments in technology, therapeutics, and process, to ensure that the goals of critical care medicine are met in the future.
SCOPUS: ed.j
Statistics for 1984 show that 59% of people die in hospitals: 27% at home and 8% in homes for the aged. This article looks at the situation in a teaching hospital, the Erasmus University Hospital in Brussels. After a brief description of the associated clinics, tables list the contributions made by teaching hospitals to increased life expectancy in the population and principal cause of death statistics. It is suggested that increasingly the hospital will be confronted with terminal cases; a return home to die is often impossible. Even if the home could be adapted to allow for the terminal care of a relative often the family finds it difficult to cope with this idea and prefers hospital based terminal care for a relative.
SUMMARY Tumour necrosis factor‐α (TNF‐α) is well established as a key mediator in the inflammatory response seen in various disease processes including sepsis. TNF‐α is involved in virtually all features of septic shock and multiple organ failure. Anti‐TNF‐α strategies are thus appealing and have been effective at reducing inflammation and morbidity in certain conditions including rheumatoid arthritis and Crohn's disease. Afelimomab is the F(ab') 2 fragment of a murine anti‐TNF‐α antibody, and has been evaluated in clinical trials in septic patients. The results suggest that the drug is well tolerated, and may be of benefit in certain groups of patients with sepsis. A large, randomised, clinical trial of afelimomab in patients with severe sepsis has recently been completed and the results are eagerly awaited. More work is necessary to identify a means of selecting which patients are most likely to benefit from this type of therapy in sepsis. ( Int J Clin Pract 2000; 54(3) : 190‐193)
